Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity

Gabriella Gardian, Lichuan Yang, Carine Cleren, Noel Y. Calingasan, P. Klivényi, M. Flint Beal

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

There is increasing evidence that administration of histone deacetylase (HDAC) inhibitors can exert neuroprotective effects by a variety of mechanisms. Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. These include several antioxidant enzymes, chaperones, and genes involved in cell survival. We examined whether administration of phenylbutyrate could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), which has been used to model Parkinson's disease. Administration of phenylbutyrate significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. These findings provide further evidence that administration of phenylbutyrate may be a useful approach for the treatment of neurodegenerative diseases.

Original languageEnglish
Pages (from-to)235-241
Number of pages7
JournalNeuroMolecular Medicine
Volume5
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Phenylbutyrates
Neuroprotective Agents
Histone Deacetylase Inhibitors
Genes
Corpus Striatum
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Tyrosine 3-Monooxygenase
Substantia Nigra
Neurodegenerative Diseases
Parkinson Disease
Dopamine
Cell Survival
Antioxidants
Neurons
4-phenyl-1,2,3,6-tetrahydropyridine
Enzymes

Keywords

  • Gene transcription
  • Histone acetylation
  • MPTP
  • Parkinson's disease
  • Phenylbutynate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Genetics
  • Cell Biology

Cite this

Gardian, G., Yang, L., Cleren, C., Calingasan, N. Y., Klivényi, P., & Beal, M. F. (2004). Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. NeuroMolecular Medicine, 5(3), 235-241. https://doi.org/10.1385/NMM:5:3:235

Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. / Gardian, Gabriella; Yang, Lichuan; Cleren, Carine; Calingasan, Noel Y.; Klivényi, P.; Beal, M. Flint.

In: NeuroMolecular Medicine, Vol. 5, No. 3, 2004, p. 235-241.

Research output: Contribution to journalArticle

Gardian, G, Yang, L, Cleren, C, Calingasan, NY, Klivényi, P & Beal, MF 2004, 'Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity', NeuroMolecular Medicine, vol. 5, no. 3, pp. 235-241. https://doi.org/10.1385/NMM:5:3:235
Gardian, Gabriella ; Yang, Lichuan ; Cleren, Carine ; Calingasan, Noel Y. ; Klivényi, P. ; Beal, M. Flint. / Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. In: NeuroMolecular Medicine. 2004 ; Vol. 5, No. 3. pp. 235-241.
@article{f2192d3e77094f49a181aa7e009460c4,
title = "Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity",
abstract = "There is increasing evidence that administration of histone deacetylase (HDAC) inhibitors can exert neuroprotective effects by a variety of mechanisms. Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. These include several antioxidant enzymes, chaperones, and genes involved in cell survival. We examined whether administration of phenylbutyrate could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), which has been used to model Parkinson's disease. Administration of phenylbutyrate significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. These findings provide further evidence that administration of phenylbutyrate may be a useful approach for the treatment of neurodegenerative diseases.",
keywords = "Gene transcription, Histone acetylation, MPTP, Parkinson's disease, Phenylbutynate",
author = "Gabriella Gardian and Lichuan Yang and Carine Cleren and Calingasan, {Noel Y.} and P. Kliv{\'e}nyi and Beal, {M. Flint}",
year = "2004",
doi = "10.1385/NMM:5:3:235",
language = "English",
volume = "5",
pages = "235--241",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity

AU - Gardian, Gabriella

AU - Yang, Lichuan

AU - Cleren, Carine

AU - Calingasan, Noel Y.

AU - Klivényi, P.

AU - Beal, M. Flint

PY - 2004

Y1 - 2004

N2 - There is increasing evidence that administration of histone deacetylase (HDAC) inhibitors can exert neuroprotective effects by a variety of mechanisms. Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. These include several antioxidant enzymes, chaperones, and genes involved in cell survival. We examined whether administration of phenylbutyrate could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), which has been used to model Parkinson's disease. Administration of phenylbutyrate significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. These findings provide further evidence that administration of phenylbutyrate may be a useful approach for the treatment of neurodegenerative diseases.

AB - There is increasing evidence that administration of histone deacetylase (HDAC) inhibitors can exert neuroprotective effects by a variety of mechanisms. Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. These include several antioxidant enzymes, chaperones, and genes involved in cell survival. We examined whether administration of phenylbutyrate could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), which has been used to model Parkinson's disease. Administration of phenylbutyrate significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. These findings provide further evidence that administration of phenylbutyrate may be a useful approach for the treatment of neurodegenerative diseases.

KW - Gene transcription

KW - Histone acetylation

KW - MPTP

KW - Parkinson's disease

KW - Phenylbutynate

UR - http://www.scopus.com/inward/record.url?scp=12344291203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344291203&partnerID=8YFLogxK

U2 - 10.1385/NMM:5:3:235

DO - 10.1385/NMM:5:3:235

M3 - Article

VL - 5

SP - 235

EP - 241

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 3

ER -